Verve Therapeutics Inc (NASDAQ:VERV) shares, rose in value, with the stock price up by 2.76% to the previous day’s close as strong demand from buyers drove the stock to $8.02.
Actively observing the price movement in the recent trading, the stock is buoying the session at $7.80, falling within a range of $7.71 and $8.7. The value of beta (5-year monthly) is 1.76. Referring to stock’s 52-week performance, its high was $19.34, and the low was $4.30. On the whole, VERV has fluctuated by 55.33% over the past month.
With the market capitalization of Verve Therapeutics Inc currently standing at about $678.58 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 4.24M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VERV’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of VERV currently trading nearly 30.69% and 35.56% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 69.78, while the 7-day volatility ratio is showing 13.05% which for the 30-day chart, stands at 9.85%. Furthermore, Verve Therapeutics Inc (VERV)’s beta value is 1.78, and its average true range (ATR) is 0.65.
A comparison of Verve Therapeutics Inc (VERV) with its peers suggests the former has fared considerably weaker in the market. VERV showed an intraday change of 2.76% in today’s session so far, and over the past year, it shrunk by -35.31%%.
Data on historical trading for Verve Therapeutics Inc (NASDAQ:VERV) indicates that the trading volumes over the past 10 days have averaged 1.79 and over the past 3 months, they’ve averaged 1.62 million. According to company’s latest data on outstanding shares, there are 84.64 million shares outstanding.
Nearly 25.47% of Verve Therapeutics Inc’s shares belong to company insiders and institutional investors own 76.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.21 million shares as on 2024-12-31, resulting in a short ratio of 8.43. According to the data, the short interest in Verve Therapeutics Inc (VERV) stood at 2004.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 17.87 million. The stock has risen by 42.11% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VERV stock heading into the next quarter.